REVERSIBILITY AND THERAPEUTIC TARGETING OF TREATMENT- EMERGENT NEUROENDOCRINE PROSTATE CANCER

$2,136,000FY2025Defense Health AgencyDOD

Dana-Farber Cancer Institute, Inc.

Investigators